MacroGenics (MGNX) News Today → Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown” (From Paradigm Press) (Ad) Free MGNX Stock Alerts $4.53 -0.14 (-3.00%) (As of 06/7/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 7 at 1:45 PM | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MacroGenics, Inc. - MGNXMay 30, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MacroGenics, Inc. - MGNXMay 29, 2024 | americanbankingnews.comMacroGenics, Inc. (NASDAQ:MGNX) Given Consensus Recommendation of "Moderate Buy" by BrokeragesMay 29, 2024 | marketbeat.comMacroGenics, Inc. (NASDAQ:MGNX) Given Consensus Rating of "Moderate Buy" by BrokeragesMacroGenics, Inc. (NASDAQ:MGNX - Get Free Report) has received a consensus rating of "Moderate Buy" from the ten ratings firms that are covering the firm, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the compMay 28, 2024 | stockhouse.comLost Money on MacroGenics, Inc.(MGNX)? Contact Levi & Korsinsky Regarding an Ongoing InvestigationMay 27, 2024 | markets.businessinsider.comLevi & Korsinsky Reminds MacroGenics, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - MGNXMay 25, 2024 | markets.businessinsider.comMGNX ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of MacroGenics, Inc. Shareholders Who Lost MoneyMay 25, 2024 | benzinga.comMacrogenics Stock (NASDAQ:MGNX), Analyst Ratings, Price Targets, PredictionsMay 25, 2024 | investorplace.com3 Biotech Stocks That Could Be Millionaire-Makers: May EditionMay 24, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: MacroGenics (MGNX) and Iovance Biotherapeutics (IOVA)May 24, 2024 | markets.businessinsider.comDemystifying Macrogenics: Insights From 14 Analyst ReviewsMay 24, 2024 | marketbeat.comMacroGenics (NASDAQ:MGNX) Given New $9.00 Price Target at BTIG ResearchBTIG Research cut their target price on MacroGenics from $24.00 to $9.00 and set a "buy" rating for the company in a research report on Friday.May 24, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: MacroGenics (MGNX) and Medtronic (MDT)May 22, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MacroGenics, Inc. - MGNXMay 17, 2024 | baystreet.caPancreatic Cancer Battle Intensifies with Biotech Sector's Advanced TreatmentsMay 16, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MacroGenics, Inc. - MGNXMay 15, 2024 | marketbeat.comResearch Analysts Set Expectations for MacroGenics, Inc.'s Q2 2024 Earnings (NASDAQ:MGNX)MacroGenics, Inc. (NASDAQ:MGNX - Free Report) - Analysts at HC Wainwright decreased their Q2 2024 earnings estimates for shares of MacroGenics in a research note issued on Monday, May 13th. HC Wainwright analyst R. Burns now forecasts that the biopharmaceutical company will post earnings of ($0.7May 14, 2024 | prnewswire.comINVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against MacroGenics, Inc. and Encourages Investors to Contact the FirmMay 14, 2024 | marketbeat.comQ1 2025 Earnings Estimate for MacroGenics, Inc. (NASDAQ:MGNX) Issued By HC WainwrightMacroGenics, Inc. (NASDAQ:MGNX - Free Report) - Investment analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of MacroGenics in a research report issued to clients and investors on Monday, May 13th. HC Wainwright analyst R. Burns expects that the biopharmaceutiMay 13, 2024 | markets.businessinsider.comHold Rating on MacroGenics Amid Safety and Efficacy Concerns for Vobra DuoMay 13, 2024 | tmcnet.comKirby McInerney LLP Announces Investigation of Shareholder Claims Against MacroGenics, Inc. (MGNX)May 13, 2024 | marketbeat.comMacroGenics (NASDAQ:MGNX) PT Lowered to $4.00 at HC WainwrightHC Wainwright reduced their price objective on shares of MacroGenics from $16.00 to $4.00 and set a "neutral" rating on the stock in a research report on Monday.May 13, 2024 | globenewswire.comMacroGenics to Participate in Upcoming Investor ConferencesMay 13, 2024 | seekingalpha.comMacroGenics: Strong Likelihood Bad News Has Caused Overreaction (Rating Upgrade)May 12, 2024 | finance.yahoo.comUS$15.10: That's What Analysts Think MacroGenics, Inc. (NASDAQ:MGNX) Is Worth After Its Latest ResultsMay 11, 2024 | wsj.comMacrogenics Inc.May 11, 2024 | msn.comBMO Capital Downgrades MacroGenics (MGNX)May 10, 2024 | marketbeat.comBarclays Trims MacroGenics (NASDAQ:MGNX) Target Price to $14.00Barclays cut their price target on MacroGenics from $25.00 to $14.00 and set an "overweight" rating on the stock in a research report on Friday.May 10, 2024 | msn.comMacroGenics Gets Downgraded Following Disappointing Prostate Cancer Trial Results: 'We Were Surprised By Reported Deaths'May 10, 2024 | msn.comStifel Downgrades MacroGenics (MGNX)May 10, 2024 | finance.yahoo.comMacroGenics, Inc. (NASDAQ:MGNX) Q1 2024 Earnings Call TranscriptMay 10, 2024 | finance.yahoo.comMacrogenics Inc (MGNX) Q1 2024 Earnings: Misses Revenue Estimates Amidst Ongoing Clinical ...May 10, 2024 | marketwatch.comMacroGenics Shares Plummet After Study Data Reveal Patient DeathsMay 10, 2024 | msn.comMacroGenics crashes after mid-stage data for prostate cancer drugMay 10, 2024 | investorplace.comWhy Is Macrogenics (MGNX) Stock Down 69% Today?May 10, 2024 | marketbeat.comMacroGenics (NASDAQ:MGNX) Stock Rating Lowered by BMO Capital MarketsBMO Capital Markets lowered shares of MacroGenics from an "outperform" rating to a "market perform" rating and decreased their price objective for the stock from $24.00 to $8.00 in a report on Friday.May 10, 2024 | finanznachrichten.deMacroGenics, Inc.: MacroGenics Provides Update on Corporate Progress, First Quarter 2024 Financial Results and Interim TAMARACK Phase 2 Study DataMay 10, 2024 | markets.businessinsider.comHold Rating on MacroGenics Amid TAMARACK Study Results and Competitive ConcernsMay 10, 2024 | markets.businessinsider.comBuy Rating on MacroGenics: Promising Clinical Data and Market Position in mCRPC TreatmentMay 10, 2024 | fool.comMacroGenics (MGNX) Q1 2024 Earnings Call TranscriptMay 9, 2024 | msn.comMGNX Stock Earnings: Macrogenics Misses EPS, Misses Revenue for Q1 2024May 9, 2024 | globenewswire.comMacroGenics Provides Update on Corporate Progress, First Quarter 2024 Financial Results and Interim TAMARACK Phase 2 Study DataMay 8, 2024 | marketbeat.comMacroGenics (NASDAQ:MGNX) Shares Down 10.8% MacroGenics (NASDAQ:MGNX) Shares Down 10.8%May 4, 2024 | marketbeat.comMacroGenics (MGNX) Scheduled to Post Quarterly Earnings on ThursdayMacroGenics (NASDAQ:MGNX) will be releasing earnings after the market closes on Thursday, May 9, Zacks reports.May 3, 2024 | finance.yahoo.comMacroGenics Announces Date of First Quarter 2024 Financial Results Conference CallMay 1, 2024 | theglobeandmail.comBiotech Innovations Aim to Combat Soaring Cancer Diagnoses by 2050April 28, 2024 | marketbeat.comMacroGenics, Inc. (NASDAQ:MGNX) Short Interest UpdateMacroGenics, Inc. (NASDAQ:MGNX - Get Free Report) saw a large growth in short interest in April. As of April 15th, there was short interest totalling 8,600,000 shares, a growth of 33.3% from the March 31st total of 6,450,000 shares. Currently, 14.7% of the company's stock are sold short. Based on an average daily trading volume, of 1,540,000 shares, the short-interest ratio is presently 5.6 days.April 26, 2024 | marketbeat.comB. Riley Begins Coverage on MacroGenics (NASDAQ:MGNX)B. Riley initiated coverage on shares of MacroGenics in a report on Friday. They set a "buy" rating and a $25.00 price target on the stock.April 26, 2024 | markets.businessinsider.comBuy Rating Affirmed for MacroGenics on Strong Oncology Pipeline and Positive Phase II Trial ResultsApril 25, 2024 | marketbeat.comMacroGenics (NASDAQ:MGNX) Trading Down 9%MacroGenics (NASDAQ:MGNX) Stock Price Down 9% Get MacroGenics News Delivered to You Automatically Sign up to receive the latest news and ratings for MGNX and its competitors with MarketBeat's FREE daily newsletter. Email Address The new masters of energy (Ad)According to one source, this new grid could soon provide energy to “one billion people in the world who don’t have access to electricity right now.” And early investors could make a fortune. Click here to get all the details. MGNX Media Mentions By Week MGNX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MGNX News Sentiment▼0.000.75▲Average Medical News Sentiment MGNX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MGNX Articles This Week▼13▲MGNX Articles Average Week Get MacroGenics News Delivered to You Automatically Sign up to receive the latest news and ratings for MGNX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Puma Biotechnology News Repare Therapeutics News Prothena News Cassava Sciences News Arcturus Therapeutics News Arcutis Biotherapeutics News Verona Pharma News Bicycle Therapeutics News Innoviva News OPKO Health News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MGNX) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredAre You Positioned For The New Energy Goldrush?Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredRSVP: Charles Payne’s Cash Flow WorkshopDid you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? ...Unstoppable Prosperity | Sponsored